Feasibility and efficacy of lidocaine cream-mediated extracorporeal shock wave therapy for postherpetic neuralgia

SUN Fuguo; YE Ling; CHEN Lu; LIU Hui

PDF(716 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2021, Vol. 32 ›› Issue (3) : 205-208.

ORIGINAL ARTICLES

Feasibility and efficacy of lidocaine cream-mediated extracorporeal shock wave therapy for postherpetic neuralgia

SUN Fuguo^1,2, YE Ling¹, CHEN Lu¹, LIU Hui¹

Author information +

History +

Abstract

Objective To evaluate the clinical feasibility and efficacy of lidocaine cream being used as a divergent extracorporeal shock wave therapy(ESWT) for postherpetic neuralgia. Methods Ninety patients with non-head and face postherpetic neuralgia were randomly divided into two groups using the block randomization method.The treatment group(n=45) received lidocaine cream-mediated ESWT while the control group(n=45) was treated with ultrasonic couplant-mediated ESWT.Both groups received medication,ESWT,pulsed radiofrequency and nerve block. The Visual Analogue Scale(VAS),hyperalgesia,Hamilton Depression Scale(HAMD),doses of opioids and pregabalin and adverse reactions were observed in both groups for 12 weeks. Results Pain score comparison: Immediately after treatment and 2 weeks after treatment, the Visual Analogue Scale (VAS) of the treatment group was 1.96±0.77 and 2.25±0.89 respectively, compared with 2.97±0.79 and 3.40±0.81 in the control group. The doses of oxycodone and pregabalin were lower in the treatment group than in the control group.There were no complications related to ESWT in either group. Conclusions Our data suggests that lidocaine cream-mediated ESWT is effective and safe for PHN patients, which can be used as a supplementary treatment of PHN in grassroots hospitals.

Key words

postherpetic neuralgia / divergent / extracorporeal shock wave therapy / lidocaine cream

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

SUN Fuguo, YE Ling, CHEN Lu, LIU Hui. Feasibility and efficacy of lidocaine cream-mediated extracorporeal shock wave therapy for postherpetic neuralgia[J]. Medical Journal of the Chinese People Armed Police Forces. 2021, 32(3): 205-208

References

[1] Werner R N, Nikkels A F, Marinovic B, et al. European consensus-based (S2k) guideline on the management of herpes zoster-guided by the european dermatology forum (EDF) in cooperation with the european academy of dermatology and venereology (EADV), Part 1: Diagnosis[J]. J Eur Acad Dermatol Venereol, 2017, 31(1):9-19.
[2] Yang F, Yu S, Fan B, et al. The epidemiology of herpes zoster and postherpetic neuralgia in China: results from a cross-sectional study[J]. Pain Ther, 2019, 8(2):249-259.
[3] Lin C S, Lin Y C, Lao H C, et al. Interventional treatments for postherpetic neuralgia: a systematic review[J]. Pain Physician, 2019, 22(3):209-228.
[4] Walewicz K, Taradaj J. The effectiveness of radial extracorporeal shock wave therapy in patients with chronic low back pain: a prospective, randomized, single-blinded pilot study[J]. Clin Interv Aging, 2019, 14:1859-1869.
[5] De Lima Morais T M, Meyer P F, De Vasconcellos L S, et al. Effects of the extracorporeal shock wave therapy on the skin: an experimental study[J]. Lasers Med Sci, 2019, 34(2):389-396.
[6] 刘水涛, 杨军, 史展, 等. 发散式体外冲击波治疗距骨骨软骨损伤的效果[J]. 武警医学, 2017, 28(7):694-697.
[7] 刘彧, 吴坤, 刘水涛, 等. 体外冲击波治疗中老年女性膝关节炎的疗效观察[J]. 武警医学, 2016, 27(4):349-352.
[8] 田俊斌, 罗斌, 赵静, 等. 不同频率分散式体外冲击波治疗带状疱疹后神经痛的临床疗效[J]. 西部医学, 2019, 31(10):1605-1608.
[9] 张芹, 杨科朋, 魏新侠, 等. 神经妥乐平联合体外冲击波疗法治疗带状疱疹后神经痛的临床疗效[J]. 北方药学, 2018, 15(7):125-126.
[10] 刘晓华, 郑拥军, 徐伟豪, 等. 体外发散式冲击波治疗带状疱疹后遗神经痛短期疗效观察[J]. 中国现代神经疾病杂志, 2013, 13(10):868-871.
[11] Hausner T, Nogradi A. The use of shock waves in peripheral nerve regeneration: new perspectives?[J]. Int Rev Neurobiol, 2013, 109:85-98.
[12] Derry S, Wiffen P J, Moore R A, et al. Topical lidocaine for neuropathic pain in adults[J]. Cochrane Database Syst Rev, 2014, 7: 10958.
[13] Casale R, Mattia C. Building a diagnostic algorithm on localized neuropathic pain (LNP) and targeted topical treatment: focus on 5% lidocaine-medicated plaster[J]. Ther Clin Risk Manag, 2014, 10:259-268.
[14] Baron R,Allegri M,lanes G, et al.The 5% lidocaine-medicated plaster: its inclusion in international treatment guidelines for treating localized neuropathic pain, and clinical evidence supporting its Use[J]. Pain Ther, 2016, 5(2):149-169.
[15] Clere F, Delorme M C, George B, et al. 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France[J]. Drugs Aging, 2011, 28(9):693-702.
[16] Lopez L M, Rivera A L, Fernandez F, et al. Shock wave-induced permeabilization of mammalian cells[J]. Phys Life Rev, 2018, 26-27:1-38.
[17] Luh J J, Huang W T, Lin K H, et al. Effects of extracorporeal shock wave-mediated transdermal local anesthetic drug delivery on rat caudal nerves[J]. Ultrasound Med Biol, 2018, 44(1):214-222.
[18] 于生元, 万有, 万琪, 等. 带状疱疹后神经痛诊疗中国专家共识[J]. 中国疼痛医学杂志, 2016, 22(3):161-167.
[19] Johnson R W, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management[J]. Expert Rev Neurother, 2007, 7(11):1581-1595.
[20] Truini A, Garcia L, Cruccu G. Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms[J]. Nat Rev Neurol, 2013, 9(10):572-582.
[21] Wasner G, Kleinert A, Binder A, et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin[J]. J Neurol, 2005, 252(6):677-686.
[22] Corallo F, Salvo S, Floridia D, et al. Assessment of spinal cord stimulation and radiofrequency: chronic pain and psychological impact[J]. Medicine (Baltimore), 2020, 99(3):e18633.
[23] Kasper S, Brasser M, Schweizer E, et al. How well do randomized controlled trial data generalize to 'real-world' clinical practice settings? A comparison of two generalized anxiety disorder studies[J]. Eur Neuropsychopharmacol, 2014, 24(1):125-132.
[24] Onakpoya I J, Lee J J, Thomas E T, et al. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials[J]. BMJ Open, 2019, 9(1):e023600.